Clinical Trial Update: Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez | Conditions: End Stage Renal Disease | Phase 3 | Status: COMPLETED